HRP20200805T1 - Spirociklički spojevi - Google Patents

Spirociklički spojevi Download PDF

Info

Publication number
HRP20200805T1
HRP20200805T1 HRP20200805TT HRP20200805T HRP20200805T1 HR P20200805 T1 HRP20200805 T1 HR P20200805T1 HR P20200805T T HRP20200805T T HR P20200805TT HR P20200805 T HRP20200805 T HR P20200805T HR P20200805 T1 HRP20200805 T1 HR P20200805T1
Authority
HR
Croatia
Prior art keywords
optionally substituted
alkyl
group
hydrogen
cancer
Prior art date
Application number
HRP20200805TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter Qinhua HUANG
Mehmet Kahraman
Deborah Helen Slee
Kevin Duane Bunker
Chad Daniel Hopkins
Joseph Robert Pinchman
Sunny Abraham
Rakesh Kumar Sit
Daniel Lee Severance
Original Assignee
Recurium Ip Holdings, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings, Llc filed Critical Recurium Ip Holdings, Llc
Publication of HRP20200805T1 publication Critical patent/HRP20200805T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20200805TT 2015-04-03 2016-03-31 Spirociklički spojevi HRP20200805T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142946P 2015-04-03 2015-04-03
PCT/US2016/025345 WO2016161160A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds
EP16774232.9A EP3277690B1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
HRP20200805T1 true HRP20200805T1 (hr) 2020-10-16

Family

ID=57007413

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200805TT HRP20200805T1 (hr) 2015-04-03 2016-03-31 Spirociklički spojevi

Country Status (25)

Country Link
US (3) US10525036B2 (enExample)
EP (1) EP3277690B1 (enExample)
JP (1) JP6737533B2 (enExample)
KR (1) KR20170132307A (enExample)
CN (1) CN107849053B (enExample)
AU (1) AU2016242940B2 (enExample)
BR (1) BR112017021194A2 (enExample)
CA (1) CA2981055A1 (enExample)
CY (1) CY1123019T1 (enExample)
DK (1) DK3277690T3 (enExample)
ES (1) ES2788160T3 (enExample)
HR (1) HRP20200805T1 (enExample)
HU (1) HUE049481T2 (enExample)
IL (1) IL254662B (enExample)
LT (1) LT3277690T (enExample)
MX (1) MX379622B (enExample)
PL (1) PL3277690T3 (enExample)
PT (1) PT3277690T (enExample)
RS (1) RS60340B1 (enExample)
RU (1) RU2745069C2 (enExample)
SG (1) SG11201707911VA (enExample)
SI (1) SI3277690T1 (enExample)
SM (1) SMT202000279T1 (enExample)
TW (1) TWI705067B (enExample)
WO (1) WO2016161160A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999451B (zh) * 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
KR20190075931A (ko) 2016-10-05 2019-07-01 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 스피로 고리 화합물
CA3045947A1 (en) * 2016-12-08 2018-06-14 Michael J. Soth Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
JP2021512109A (ja) * 2018-01-31 2021-05-13 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体修飾因子およびその使用
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
IL301817A (en) 2020-10-13 2023-06-01 Univ Johns Hopkins Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP5380296B2 (ja) 2006-11-17 2014-01-08 ポリエラ コーポレイション ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法
CN102015693B (zh) * 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
CA2774769A1 (en) * 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2013033059A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
CN103130775B (zh) * 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
KR20190075931A (ko) 2016-10-05 2019-07-01 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 스피로 고리 화합물

Also Published As

Publication number Publication date
RU2017133973A3 (enExample) 2019-07-17
CA2981055A1 (en) 2016-10-06
JP2018511613A (ja) 2018-04-26
BR112017021194A2 (pt) 2019-01-08
PL3277690T3 (pl) 2020-08-24
MX2017012553A (es) 2018-04-11
AU2016242940A1 (en) 2017-10-26
CY1123019T1 (el) 2021-10-29
SG11201707911VA (en) 2017-10-30
RU2017133973A (ru) 2019-05-06
US10525036B2 (en) 2020-01-07
PT3277690T (pt) 2020-03-24
HK1256671A1 (en) 2019-09-27
IL254662A0 (en) 2017-11-30
ES2788160T3 (es) 2020-10-20
AU2016242940B2 (en) 2020-11-05
US20190201380A1 (en) 2019-07-04
DK3277690T3 (da) 2020-05-04
LT3277690T (lt) 2020-06-10
JP6737533B2 (ja) 2020-08-12
WO2016161160A1 (en) 2016-10-06
TWI705067B (zh) 2020-09-21
SMT202000279T1 (it) 2020-07-08
US20180207132A1 (en) 2018-07-26
US20200268714A1 (en) 2020-08-27
KR20170132307A (ko) 2017-12-01
RS60340B1 (sr) 2020-07-31
EP3277690B1 (en) 2020-02-26
RU2745069C2 (ru) 2021-03-18
MX379622B (es) 2025-03-11
CN107849053B (zh) 2020-10-30
SI3277690T1 (sl) 2020-07-31
IL254662B (en) 2021-02-28
TW201710261A (zh) 2017-03-16
EP3277690A4 (en) 2018-08-22
HUE049481T2 (hu) 2020-09-28
CN107849053A (zh) 2018-03-27
US10493060B2 (en) 2019-12-03
EP3277690A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
HRP20210791T2 (hr) 1-cijano-pirolidin spojevi kao usp30 inhibitori
IL303196B2 (en) Heteroaryl-substituted pyridines and methods of use
IL187690A (en) Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer
JP2021502356A5 (enExample)
AU2026201001A1 (en) CDK inhibitors
RU2017133973A (ru) Спироциклические соединения
HRP20150185T1 (hr) Inhibitori kinaza koji reguliraju signalne puteve u apoptozi
JP2019513135A5 (enExample)
JP2018510183A5 (enExample)
HRP20180382T1 (hr) Inhibitori protein kinaze
JP2018507861A5 (enExample)
FI3436461T3 (fi) Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
JP2021535134A5 (enExample)
CN111417394B (zh) 苯并咪唑衍生物及其用途
HRP20200440T1 (hr) 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori
ME02402B (me) Derivati azola
RU2017134379A (ru) Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
JP2018511613A5 (enExample)
US20180251431A1 (en) 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels
KR20230104781A (ko) Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
RU2440349C2 (ru) Производные морфолинопиримидина, полезные для лечения пролиферативных нарушений
US20240383875A1 (en) Benzimidazole Pyridine Derivatives
RU2653500C2 (ru) Ингибиторы тирозинкиназы брутона
JP2006522775A5 (enExample)
RU2025126825A (ru) Новые производные гетероциклических аминов и фармацевтическая композиция, включающая их